Ipilimumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ipilimumab and local guidelines before prescribing.

Immune checkpoint inhibitor

Mechanism

CTLA-4 inhibitor augmenting T-cell activation.

Uses

Melanoma, renal cell carcinoma (combination), other cancers.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Immune-related colitis, hepatitis, dermatitis, endocrinopathies (hypophysitis), pneumonitis.

Interactions

Corticosteroids reduce effect.

Contraindications and cautions

Autoimmune disease caution

Monitoring

LFT, TFT, cortisol, U&E

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive; steroids

Special advice

Severe diarrhoea needs urgent assessment; steroids early; endocrinopathy cover.

More from the textbook: uses, cautions and other points
Where it is discussed in the book